Publications by authors named "G Paganelli"
Introduction: Lu-PRRT in neuroendocrine tumors is usually delivered with a total cumulative activity (TCA) of 29.6 GBq, divided into 4 cycles and with fixed interval between cycles (IBCs) of 8 weeks. Based on previous radiobiological studies, reducing IBC could improve efficacy without increasing toxicity.
View Article and Find Full Text PDFArticle Synopsis
- Radiopharmaceutical theranostic treatments are becoming increasingly popular for cancer therapy, especially for CNS tumors, and rely on the internal release of radiation to achieve clinical effects.
- Accurate absorbed dose calculations are crucial for understanding how the treatment works and customizing it for individual patients.
- The article emphasizes the advancements in internal dosimetry techniques, the importance of consistent data collection for treatment planning, and the challenges faced in applying these methods effectively.
Purpose: to assess the utility of response monitoring to enzalutamide by using [Ga]Ga-PSMA PET in mCRPC patients treated with enzalutamide as first-line therapy.
Methods: patients underwent [Ga]Ga-PSMA PET less than 8 weeks before and 3 months after starting enzalutamide. On the basis of EAU/EANM criteria, patients were categorized as PSMA responders (PET-R) or PSMA non-responders (PET-NR), whilst, based on PSA, they were classified as biochemical responders (PSA-R) or non-responders (PSA-NR).
Recurrence of meningiomas after surgery and radiotherapy deserves specific attention because of the lack of active third-line therapies. Somatostatin receptors are usually overexpressed on the cell membrane of meningiomas, and this has led the way to a radionuclide theranostic approach. Diagnoses with Ga-DOTA-octreotide and peptide receptor radionuclide therapy (PRRT) with Y/Lu-DOTA-octreotide are currently possible options within experimental protocols or as compassionate use in small patient groups.
View Article and Find Full Text PDF